par Verdikt, Roxane ;Bendoumou, Maryam ;Bouchat, Sophie ;Nestola, Lorena ;Pasternak, Alexander O;Darcis, Gilles ;Avettand-Fenoel, Veronique;Vanhulle, Caroline ;Ait-Ammar, Amina ;Santangelo, Marion ;Plant, Estelle ;Douce, Valentin Le;Delacourt, Nadège ;Cicilionyte, Aurelija;Necsoi, Coca;Corazza, Francis ;Passaes, Caroline Pereira Bittencourt;Schwartz, Christian;Bizet, Martin ;Fuks, François ;Sáez-Cirión, Asier;Rouzioux, Christine;De Wit, Stéphane ;Berkhout, Ben;Gautier, Virginie;Rohr, Olivier;Van Lint, Carine
Référence EBioMedicine, 79, page (103985)
Publication Publié, 2022-04-01
Référence EBioMedicine, 79, page (103985)
Publication Publié, 2022-04-01
Article révisé par les pairs
Résumé : | The multiplicity, heterogeneity, and dynamic nature of human immunodeficiency virus type-1 (HIV-1) latency mechanisms are reflected in the current lack of functional cure for HIV-1. Accordingly, all classes of latency-reversing agents (LRAs) have been reported to present variable ex vivo potencies. Here, we investigated the molecular mechanisms underlying the potency variability of one LRA: the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-AzadC). |